Rigel Pharma

$1.02 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Rigel Pharma

Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.

Stock Analysis

last close $1.12
1-mo return -43.4%
3-mo return -63.8%
avg daily vol. 14.52M
52-week high 4.62
52-week low 0.64
market cap. $189M
forward pe -
annual div. -
roe -199.4%
ltg forecast -
dividend yield -
annual rev. $85M
inst own. 83.4%

Subscribe now for daily local and international financial news